{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:50:56Z","timestamp":1787028656019,"version":"build-2736575974"},"reference-count":40,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery (CRS) has been reported to improve survival in patients with peritoneal carcinomatosis. This study aimed to investigate the morbidity and mortality rates of CRS with HIPEC in patients with ovarian cancers. Methods: We retrospectively reviewed the medical records of patients who underwent CRS with HIPEC for ovarian cancer from January 2013 to July 2021 at two tertiary institutions. The morbidities and mortalities that occurred within 30 days after HIPEC and the clinical and operative factors related to morbidities were investigated. Results: A total of 155 procedures in 151 patients were included in this study. The median age was 55 years and the median score of the peritoneal carcinomatosis index was eight points. Morbidities of grade \u22653 within 30 days of HIPEC occurred in 18 patients (11.6%). The most common severe morbidity was wound infection (3.2%), followed by pleural effusion (1.9%) and postoperative hemorrhage (1.9%). Within the 30-day postoperative period, there were no reported mortality cases. There were statistical differences in age, length of stay, peritoneal carcinomatosis index, bowel resection, operation time, and completeness of cytoreduction between the patients and severe morbidity. However, in the multivariate logistic analysis, none of the factors showed a statistically significant relationship with the occurrence of severe morbidity. Conclusions: The morbidity and mortality rates of CRS with HIPEC in gynecologic cancer patients were relatively low compared to those in previous reports. Further studies about the possible risk factors are needed.<\/jats:p>","DOI":"10.3390\/jcm14051782","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T04:29:59Z","timestamp":1741321799000},"page":"1782","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Morbidity and Mortality Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6950-0693","authenticated-orcid":false,"given":"Migang","family":"Kim","sequence":"first","affiliation":[{"name":"Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam 13520, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0297-3116","authenticated-orcid":false,"given":"Yong Jae","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Institute of Women\u2019s Life Medical Science, Yonsei University College of Medicine, Seoul 06229, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0842-9218","authenticated-orcid":false,"given":"Ki Eun","family":"Seon","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Institute of Women\u2019s Life Medical Science, Yonsei University College of Medicine, Seoul 06229, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunghoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Institute of Women\u2019s Life Medical Science, Yonsei University College of Medicine, Seoul 06229, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Lee","sequence":"additional","affiliation":[{"name":"Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam 13520, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun","family":"Park","sequence":"additional","affiliation":[{"name":"Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam 13520, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4509-6731","authenticated-orcid":false,"given":"Min Chul","family":"Choi","sequence":"additional","affiliation":[{"name":"Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, School of Medicine, CHA University, Seongnam 13520, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7948-1350","authenticated-orcid":false,"given":"Jung-Yun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Institute of Women\u2019s Life Medical Science, Yonsei University College of Medicine, Seoul 06229, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.3802\/jgo.2020.31.e58","article-title":"Incidence and predictors of peritoneal metastases of gynecological origin: A population-based study in the Netherlands","volume":"31","author":"Burg","year":"2020","journal-title":"J. Gynecol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_4","first-page":"CD005340","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","volume":"11","author":"Jaaback","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/ijgc-00009577-200705000-00003","article-title":"A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer","volume":"17","author":"Hess","year":"2007","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","article-title":"Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial","volume":"29","author":"Antonio","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ygyno.2020.09.022","article-title":"Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States","volume":"159","author":"Charo","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ygyno.2018.09.007","article-title":"It\u2019s time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer","volume":"151","author":"Zivanovic","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1245\/s10434-017-6313-5","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Elderly: Is It Reasonable? A Meta-Analysis","volume":"25","author":"Veziant","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","article-title":"Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patients","volume":"39","author":"Bakrin","year":"2013","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejso.2015.11.006","article-title":"Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center","volume":"42","author":"Rubio","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.3802\/jgo.2019.30.e3","article-title":"Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: A protocol-based pilot study","volume":"30","author":"Lee","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lee, Y.J., Seon, K.E., Jung, D.C., Lee, J.-Y., Nam, E.J., Kim, S.W., Kim, S., and Kim, Y.T. (2022). Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.936099"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"676.e1","DOI":"10.1016\/j.ajog.2007.10.495","article-title":"Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer","volume":"197","author":"Aletti","year":"2007","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ygyno.2007.05.032","article-title":"A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model","volume":"107","author":"Aletti","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1245\/s10434-014-4141-4","article-title":"Development and assessment of Memorial Sloan Kettering Cancer Center\u2019s Surgical Secondary Events grading system","volume":"22","author":"Strong","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ejso.2019.11.520","article-title":"Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis","volume":"46","author":"Machida","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.3802\/jgo.2022.33.e53","article-title":"Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: A systematic review and meta-analysis","volume":"33","author":"Kengsakul","year":"2022","journal-title":"J. Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ygyno.2022.03.023","article-title":"Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center","volume":"165","author":"Norppa","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3390\/curroncol31020048","article-title":"Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA)","volume":"31","author":"Campos","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ejso.2019.10.032","article-title":"Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies","volume":"46","author":"Somashekhar","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/02656736.2020.1795277","article-title":"Sodium thiosulfate protects from renal impairement following hyperthermic intraperitoneal chemotherapy (HIPEC) with Cisplatin","volume":"37","author":"Laplace","year":"2020","journal-title":"Int. J. Hyperth."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lim, P.-Q., Han, I.-H., Seow, K.-M., and Chen, K.-H. (2022). Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231710078"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.21037\/jgo-2020-03","article-title":"Intraperitoneal paclitaxel: Pharmacology, clinical results and future prospects","volume":"12","author":"Sugarbaker","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.surge.2020.08.016","article-title":"Survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A systematic review and discussion of latest controversies","volume":"19","author":"Flood","year":"2021","journal-title":"Surgeon"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Elias","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","article-title":"Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy","volume":"17","author":"Glehen","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1002\/cncr.25356","article-title":"Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1290 patients","volume":"116","author":"Glehen","year":"2010","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1245\/s10434-008-0299-y","article-title":"Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: Interim analysis of a phase II study","volume":"16","author":"Lim","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_34","first-page":"99","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A review of factors contributing to morbidity and mortality","volume":"7","author":"Newton","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1245\/s10434-008-0105-x","article-title":"Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer","volume":"15","author":"Franko","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1515\/pp-2020-0139","article-title":"Predictors of morbidity and mortality in patients submitted to cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for ovarian carcinomatosis: A multicenter study","volume":"6","author":"Accarpio","year":"2021","journal-title":"Pleura Peritoneum"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"571.e1","DOI":"10.1016\/j.ajog.2019.02.019","article-title":"Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer","volume":"220","author":"Cham","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1245\/s10434-017-5821-7","article-title":"Major Postoperative Complications Are a Risk Factor for Impaired Survival after CRS\/HIPEC","volume":"24","author":"Schneider","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1245\/s10434-014-4297-y","article-title":"Serious Postoperative Complications Affect Early Recurrence After Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Carcinomatosis","volume":"22","author":"Simkens","year":"2015","journal-title":"Ann. Surg. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1782\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:48:35Z","timestamp":1760028515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051782"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051782","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]}}}